不同组慢性乙型肝炎患者的血清微小RNA-210水平

Serum microRNA-210 levels in different groups of chronic hepatitis B patients.

作者信息

Yu Fujun, Yang Jianhuan, Ouyang Jinsheng, Zheng Yihu, Chen Bicheng, Li Guojun, Lu Zhongqiu, Dong Peihong, Zheng Jianjian

机构信息

Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, PR China.

Department of Children's internal medicine, The Second Affiliated Hospital & Yuying Children's hospital of Wenzhou Medical University, Wenzhou 325000, PR China.

出版信息

Clin Chim Acta. 2015 Oct 23;450:203-9. doi: 10.1016/j.cca.2015.08.022. Epub 2015 Aug 28.

DOI:10.1016/j.cca.2015.08.022

PMID:26319884

Abstract

BACKGROUND

It has been reported that hepatitis B virus (HBV) replication can be suppressed by microRNA-210 (miR-210). However, whether serum miR-210 levels can serve as disease parameters in patients with chronic hepatitis B (CHB) remains unclear.

METHODS

Serum miR-210 levels were quantified in 115 CHB patients and 20 healthy controls by real-time PCR.

RESULTS

We found that serum miR-210 levels can discriminate the different groups of CHB patients from healthy control (P<0.05), as well as patients with HBe antigen positive from those with HBe antigen negative (P<0.05). Serum miR-210 levels correlated with HBV DNA and HBs antigen (r=0.525, P<0.001 and r=0.348, P<0.001). Notably, inactive carrier patients with high (>3500 IU/mL) or low (<3500 IU/mL) levels of HBs antigen were differentiated by serum miR-210 levels (P<0.05). Moreover, serum miR-210 levels correlated with liver inflammatory activity markers including alanine aminotransferase (ALT) and HAI score. However, there was no correlation of serum miR-210 levels with parameters of liver function including serum albumin, international normalized ratio and bilirubin, as well as the stages of liver fibrosis.

CONCLUSIONS

Serum miR-210 can be used as an indicator of HBV replication and translation, and a potential marker of necroinflammation in patients with CHB.

摘要

背景

据报道，微小RNA-210（miR-210）可抑制乙型肝炎病毒（HBV）复制。然而，血清miR-210水平能否作为慢性乙型肝炎（CHB）患者的疾病参数仍不清楚。

方法

采用实时荧光定量PCR检测115例CHB患者和20例健康对照者血清miR-210水平。

结果

我们发现血清miR-210水平可区分CHB患者与健康对照的不同组（P<0.05），以及HBe抗原阳性患者与HBe抗原阴性患者（P<0.05）。血清miR-210水平与HBV DNA和HBs抗原相关（r=0.525，P<0.001；r=0.348，P<0.001）。值得注意的是，血清miR-210水平可区分HBs抗原水平高（>3500 IU/mL）或低（<3500 IU/mL）的非活动性携带者患者（P<0.05）。此外，血清miR-210水平与包括丙氨酸氨基转移酶（ALT）和HAI评分在内的肝脏炎症活动标志物相关。然而，血清miR-210水平与包括血清白蛋白、国际标准化比值和胆红素在内的肝功能参数以及肝纤维化分期无关。